CLAIMS

What is claimed is:

1. A composition comprising a 5-HT_{2A} antagonist, a norepinephrine-dopamine reuptake inhibitor, an oxytocin receptor (OXTR) agonist, and a pharmaceutically acceptable carrier.
2. The composition of claim 1, wherein the 5-HT_{2A} antagonist is also a 5-HT_{IA} receptor agonist.
3. The composition of claim 1, comprising trazodone, bupropion, and oxytocin.
4. The composition of claim 1, comprising bupropion in a dosage range of 200-450 mg.
5. The composition of claim 1, comprising trazodone in a dosage range of 25-450 mg.
6. The composition of claim 1, comprising oxytocin in a dosage range of 4-400 International Units.
7. The composition of claim 1, comprising trazodone in a dosage range of 1-450 mg, bupropion in a dosage range of 1-450 mg, and oxytocin in a dosage range of 4-400 International Units.
8. A method of making a composition comprising combining a 5-HT_{IA} agonist, a 5-HT_{2A} antagonist, a norepinephrine-dopamine reuptake inhibitor, an oxytocin receptor (OXTR) agonist, and a pharmaceutically acceptable carrier.
9. The method of claim 8, comprising combining bupropion, trazodone, oxytocin, and a pharmaceutically acceptable carrier.
10. Use of a combination of a 5-HT_{2A} antagonist, a norepinephrine-dopamine reuptake inhibitor, and an oxytocin receptor (OXTR) agonist in the manufacture of a composition for ~~A method of~~ treating a sexual disorder in a subject. ~~comprising administering to the subject a composition according to claim 1.~~
11. The use ~~method~~ of claim 10, wherein the sexual disorder is hypoactive sexual desire disorder (HSDD).
12. The use~~method~~ of claim 10, wherein the sexual disorder is female orgasm disorder (FOD).
13. The use~~method~~ of claim 10, wherein the sexual disorder is female sexual arousal disorder (FSAD).
14. The use~~method~~ of claim 10, wherein the sexual disorder is sexual pain dysfunction.
15. The use~~method~~ of claim 10, wherein the sexual disorder is male HSDD.

16. Use of a combination of a 5-HT_{2A} antagonist, a norepinephrine-dopamine reuptake inhibitor, and an oxytocin receptor (OXTR) agonist in the manufacture of a composition for ~~A method of~~ treating male sexual performance anxiety in a subject. ~~comprising administering to the subject a composition according to claim 1.~~

17. Use of a combination of a 5-HT_{2A} antagonist, a norepinephrine-dopamine reuptake inhibitor, and an oxytocin receptor (OXTR) agonist in the manufacture of a composition for ~~A method of~~ treating a diagnostic and statistical manual of mental disorders (DSM-IV) disorder. ~~in a subject comprising administering to the subject a composition according to claim 1.~~

18. Use of a combination of a 5-HT_{2A} antagonist, a norepinephrine-dopamine reuptake inhibitor, and an oxytocin receptor (OXTR) agonist in the manufacture of a composition for ~~A method of~~ treating erectile dysfunction (ED) in a subject ~~comprising administering to the subject a composition according to claim 1~~.

19. Use of a combination of a 5-HT_{2A} antagonist, a norepinephrine-dopamine reuptake inhibitor, and an oxytocin receptor (OXTR) agonist in the manufacture of a composition for ~~A method of~~ treating male orgasmic disorder (MOD) in a subject. ~~comprising administering to the subject a composition according to claim 1~~.

20. Use of a combination of a 5-HT_{2A} antagonist, a norepinephrine-dopamine reuptake inhibitor, and an oxytocin receptor (OXTR) agonist in the manufacture of a composition for ~~A method of~~ treating a cognitive disorder in a subject. ~~comprising administering to the subject a composition according to claim 1.~~

21. The use of~~method in~~ claim 20, wherein the cognitive disorder is dementia.

22. The use of~~method in claim~~ 21, wherein the dementia is Alzheimer's disease, frontotemporal lobar degeneration, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, multi-infarct dementia, dementia resulting from infections affecting the central nervous system, dementia resulting from chronic drug use, dementia resulting from hydrocephalus, dementia resulting from brain injury, or dementia resulting from a brain tumor.

23. The use of~~method in~~ claim 20, wherein the cognitive disorder is cognitive disability.

24. The use of~~method in~~ claim 23, wherein the cognitive disability is schizophrenia, schizoaffective disorder, bipolar disorder, or major depression.

25. The use of~~method in~~ claim 20, wherein the cognitive disorder is developmental cognitive impairment.

26. The use of~~method in~~ claim 25, wherein the developmental cognitive impairment is Autism, Asperger's syndrome, or pervasive developmental disorder.

27. The use of~~method in~~ claim 20, wherein the cognitive disorder is mild cognitive decline.

28. Use of a combination of a 5-HT_{2A} antagonist, a norepinephrine-dopamine reuptake inhibitor, and an oxytocin receptor (OXTR) agonist in the manufacture of a composition for ~~A method of~~ enhancing cognition in a subject. ~~comprising administering to the subject a composition according to claim 1.~~

29. The use of~~method in~~ claim 28, wherein enhancing cognition is improving mental activities such as attention, perception, learning, memory, language, planning, decision-making, organization, conceptualization, reorganization, synthesis of facts, synthesis of data, recall, calculation, spatiotemporal visualization, mental flexibility, creativity, or the ability to accept challenging intellectual or cultural pursuits.

30. The use ~~method~~ of any one of claims 10, 16, 17, 18, 19, 20, or 28 wherein the composition is administered orally.

31. The use~~method~~ of any one of claims 10, 16, 17, 18, 19, 20, or 28 wherein the composition is administered topically.

32. The use~~method~~ of any one of claims 10, 16, 17, 18, 19, 20, or 28 wherein the subject is diagnosed and being treated for depression.

33. The use~~method~~ of any one of claims 10, 16, 17, 18, 19, 20, or 28 wherein the subject is not undergoing treatment for depression.

34. The use~~method~~ of any one of claims 10, 16, 17, 18, 19, 20, or 28 wherein the subject is concurrently prescribed an additional therapeutic agent.

35. The use~~method~~ of any one of claims 10, 16, 17, 18, 19, 20, or 28 wherein the subject is concurrently not prescribed an additional therapeutic agent.

36. The use of any one of claims 10 to 35, wherein the combination further comprises a 5-HT_{1A} agonist.

37~~36~~. An extended release composition comprising a 5-HT_2A antagonist, a norepinephrine-dopamine reuptake inhibitor, an oxytocin receptor (OXTR) agonist, and a pharmaceutically acceptable carrier.

38~~37~~. The composition of claim 1, wherein the composition is suitable for oral administration.

39~~38~~. The composition of claim 1, wherein the composition is suitable for topical administration.

4039. A kit comprising a composition according to claim 1 and a label providing instructions for administration of the composition to a subject for treating or ameliorating a sexual disorder or symptoms thereof in the subject.

4140. A kit comprising a composition according to claim 1 and a label providing instructions for administration of the composition to a subject for treating or ameliorating male sexual performance anxiety or symptoms thereof in the subject.

4241. A kit comprising a composition according to claim 1 and a label providing instructions for administration of the composition to a subject for treating or ameliorating cognitive disorders or symptoms thereof in the subject.

4342. A kit comprising a composition according to claim 1 and a label providing instructions for administration of the composition to a subject for enhancing cognition or symptoms thereof in the subject.

4443. A single dosage composition comprising a 5-HT_2A antagonist, a norepinephrine-dopamine reuptake inhibitor, an oxytocin receptor (OXTR) agonist, and a pharmaceutically acceptable carrier.

~~44. A method of treating a sexual disorder in a subject comprising administering to the subject a 5-HT_{2A} antagonist, a norepinephrine-dopamine reuptake inhibitor, and an oxytocin receptor (OXTR) agonist.~~

~~45. A method of treating a diagnostic and statistical manual of mental disorders (DSM-IV) disorder in a subject comprising administering to the subject a 5-HT_{2A} antagonist, a norepinephrine-dopamine reuptake inhibitor, and an oxytocin receptor (OXTR) agonist.~~

~~46. A method of treating erectile dysfunction (ED) in a subject comprising administering to the subject a 5-HT_{2A} antagonist, a norepinephrine-dopamine reuptake inhibitor, and an oxytocin receptor (OXTR) agonist.~~

~~47. A method of treating male orgasmic disorder (MOD) in a subject comprising administering to the subject a 5-HT_2A antagonist, a norepinephrine-dopamine reuptake inhibitor, and an oxytocin receptor (OXTR) agonist.~~

~~48. A method of treating male sexual performance anxiety in a subject comprising administering to the subject a 5-HT_{2A} antagonist, a norepinephrine-dopamine reuptake inhibitor, and an oxytocin receptor (OXTR) agonist.~~

~~49. A method of treating cognitive disorders in a subject comprising administering to the subject a 5-HT_{2A} antagonist, a norepinephrine-dopamine reuptake inhibitor, and an oxytocin receptor (OXTR) agonist.~~

~~50. A method of enhancing cognition in a subject comprising administering to the subject a 5-HT_{2A} antagonist, a norepinephrine-dopamine reuptake inhibitor, and an oxytocin receptor (OXTR) agonist.~~

4551. A method of making a composition comprising combining a 5-HT_{1A} receptor agonist and a pharmaceutically acceptable carrier such that the composition comprises a range of 25- 450mg of a 5-HT_{1A} receptor agonist, a norepinephrine-dopamine reuptake inhibitor, and an oxytocin receptor (OXTR) agonist.

4652. A method of making a composition comprising combining a 5-HT_{1A} agonist/5-HT_{2A} antagonist and a pharmaceutically acceptable carrier such that the composition comprises a range of 25-450 mg of a 5-HT_{1A} agonist/5-HT_{2A} antagonist~~5-HT_{2A} antagonist~~, a norepinephrine-dopamine reuptake inhibitor, and an oxytocin receptor (OXTR) agonist.

4753. A method of making a composition comprising combining a norepinephrine-dopamine reuptake inhibitor and a pharmaceutically acceptable carrier such that the composition comprises a range of 200-450 mg of a norepinephrine-dopamine reuptake inhibitor, a 5-HT_{2A} antagonist, and an oxytocin receptor (OXTR) agonist.

4854. A method of making a composition comprising combining an oxytocin receptor (OXTR) agonist and a pharmaceutically acceptable carrier such that the composition comprises a range of 4-400 International Units of an oxytocin receptor (OXTR) agonist, a norepinephrine-dopamine reuptake inhibitor, and a 5-HT_{2A} antagonist.

4955. Use of an oxytocin receptor (OXTR) agonist in the manufacture of a composition for ~~A method of~~ treating a sexual disorder in a subject, ~~comprising administering to the subject a composition of an oxytocin receptor (OXTR) agonist and a pharmaceutically acceptable carrier~~wherein the sexual disorder is sexual pain dysfunction, or male sexual performance anxiety. ~~.~~

~~56. The method of claim 55, wherein the sexual disorder is hypoactive sexual desire disorder (HSDD).~~

~~57. The method of claim 55, wherein the sexual disorder is female orgasm disorder (FOD).~~

~~58. The method of claim 55, wherein the sexual disorder is female sexual arousal disorder (FSAD).~~

~~59. The method of claim 55, wherein the sexual disorder is sexual pain dysfunction.~~

~~60. The method of claim 55, wherein the sexual disorder is male HSDD.~~

~~61. A method of treating male sexual performance anxiety in a subject comprising administering to the subject a composition comprising an oxytocin receptor (OXTR) agonist and a pharmaceutically acceptable carrier.~~

~~62. A method of treating male orgasmic disorder (MOD) in a subject comprising administering to the subject a composition comprising an oxytocin receptor (OXTR) agonist and a pharmaceutically acceptable carrier.~~

~~63. A method of treating a diagnostic and statistical manual of mental disorders (DSM-IV) disorder in a subject comprising administering to the subject a composition comprising an oxytocin receptor (OXTR) agonist and a pharmaceutically acceptable carrier.~~

~~64. A method of treating erectile dysfunction (ED) in a subject comprising administering to the subject a composition comprising an oxytocin receptor (OXTR) agonist and a pharmaceutically acceptable carrier.~~

50~~65~~. Use of an oxytocin receptor (OXTR) agonist in the manufacture of a composition for ~~A method of~~ treating a cognitive disorder~~s~~ in a subject, ~~comprising administering to the subject a composition comprising an oxytocin receptor (OXTR) agonist and a pharmaceutically acceptable carrier~~wherein the cognitive disorder is selected from the group consisting of Alzheimer's disease, frontotemporal lobar degeneration dementia with Lewy bodies, Parkinson's disease, Huntington's disease, multi-infarct dementia, dementia resulting from infections affecting the central nervous system, dementia resulting from chronic drug use, dementia resulting from hydrocephalus, dementia resulting from brain injury, or dementia resulting from a brain tumor, or Autism.

~~66. The method in claim 65, wherein the cognitive disorder is dementia.~~

~~67. The method in claim 66, wherein the dementia is Alzheimer's disease, frontotemporal lobar degeneration, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, multi-infarct dementia, dementia resulting from infections affecting the central nervous system, dementia resulting from chronic drug use, dementia resulting from hydrocephalus, dementia resulting from brain injury, or demntia resulting from a brain tumor.~~

~~68. The method in claim 65, wherein the cognitive disorder is cognitive disability.~~

~~69. The method in claim 68, wherein the cognition disability is schizophrenia, schizoaffective disorder, bipolar disorder, or major depression.~~

~~70. The method in claim 65, wherein the cognitive disorder is developmental cognitive impairment.~~

~~71. The method in claim 70, wherein the developmental cognitive impairment is Autism, Asperger's syndrome, or pervasive developmental disorder.~~

~~72. The method in claim 65, wherein the cognitive disorder is mild cognitive decline.~~

51~~73~~. Use of an oxytocin receptor (OXTR) agonist in the manufacture of a composition for ~~A method of~~ enhancing non-social cognition in a subject. ~~comprising administering to the subject a composition comprising an oxytocin receptor (OXTR) agonist and a pharmaceutically acceptable carrier.~~

52~~74~~. The use of ~~method in~~ claim 51~~73~~, wherein enhancing cognition is improving mental activities such as attention, perception, learning, memory, language, planning, decision-making, organization, conceptualization, reorganization, synthesis of facts, synthesis of data, recall, calculation, spatiotemporal visualization, mental flexibility, creativity, or the ability to accept challenging intellectual or cultural pursuits.

53~~75~~. The use ~~method~~ of any one of claims 49-52 ~~55, 61, 62, 63, 64, 65, or 73~~, wherein the composition is administered orally.

54~~76~~. The use~~method~~ of any one of claims 49-52 ~~55, 61, 62, 63, 64, 65, or 73~~, wherein the composition is administered topically.

55~~77~~. The use~~method~~ of any one of claims 49-52 ~~55, 61, 62, 63, 64, 65, or 73~~, wherein the subject is diagnosed and being treated for depression.

56~~78~~. The use~~method~~ of any one of claims 49-52 ~~55, 61, 62, 63, 64, 65, or 73~~, wherein the subject is not undergoing treatment for depression.

57~~79~~. The use~~method~~ of any one of ~~claims~~ claims 49-52 ~~55, 61, 62, 63, 64, 65, or 73~~, wherein the subject is concurrently prescribed an additional therapeutic agent.

58~~80~~. The use~~method~~ of any one of claims 49-52 ~~55, 61, 62, 63, 64, 65, or 73~~, wherein the subject is concurrently not prescribed an additional therapeutic agent.

59~~81~~. A kit comprising a composition comprising an oxytocin receptor (OXTR) agonist, a pharmaceutically acceptable carrier, and a label providing instructions for administration of the composition to a subject for treating or ameliorating a sexual disorder or symptoms thereof in the subject, wherein the sexual disorder is sexual pain dysfunction, or male sexual performance anxiety.

~~82. A kit comprising a composition an oxytocin receptor (OXTR) agonist, a pharmaceutically acceptable carrier, and a label providing instructions for administration of the~~

~~composition to a subject for treating or ameliorating male sexual performance anxiety or symptoms thereof in the subject.~~

~~83. A kit comprising a composition an oxytocin receptor (OXTR) agonist, a pharmaceutically acceptable carrier, and a label providing instructions for administration of the composition to a subject for treating or ameliorating cognitive disorders or symptoms thereof in the subject.~~

60~~84~~. A kit comprising a composition comprising an oxytocin receptor (OXTR) agonist, a pharmaceutically acceptable carrier, and a label providing instructions for administration of the composition to a subject for enhancing non-social cognition or symptoms thereof in the subject.

~~85. A method of treating a sexual disorder in a subject comprising administering to the subject an oxytocin receptor (OXTR) agonist.~~

~~86. A method of treating male sexual performance anxiety in a subject comprising administering to the subject an oxytocin receptor (OXTR) agonist.~~

~~87. A method of treating male orgasmic disorder (MOD) in a subject comprising administering to the subject an oxytocin receptor (OXTR) agonist.~~

~~88. A method of treating a diagnostic and statistical manual of mental disorders (DSM-IV) disorder in a subject comprising administering to the subject an oxytocin receptor (OXTR) agonist.~~

~~89. A method of treating erectile dysfunction (ED) in a subject comprising administering to the subject an oxytocin receptor (OXTR) agonist.~~

~~90. A method of treating cognitive disorders in a subject comprising administering to the subject an oxytocin receptor (OXTR) agonist.~~

~~91. A method of enhancing cognition in a subject comprising administering to the subject an oxytocin receptor (OXTR) agonist.~~

~~92. A method of making a composition comprising combining an oxytocin receptor (OXTR) agonist and a pharmaceutically acceptable carrier such that the composition comprises a range of 4-400 International Units of an oxytocin receptor (OXTR) agonist.~~

61~~93~~. A composition comprising a 5-HT_{2A} antagonist, an oxytocin receptor (OXTR) agonist, and a pharmaceutically acceptable carrier.

62~~94~~. The composition of claim 61~~93~~, wherein the ~~5-HT_{1A} agonist/~~5-HT_2A antagonist is also a 5- HT_{1A} receptor agonist.

63~~95~~. The composition of claim 61~~93~~, comprising trazodone and oxytocin.

64~~96~~. The composition of claim 61~~93~~, comprising trazodone in a dosage range of 25-450 mg.

65~~97~~. The composition of claim 61~~93~~, comprising oxytocin in a dosage range of 4-400 International Units.

66~~98~~. The composition of claim 61~~93~~, comprising trazodone in a dosage range of 25-450 mg and oxytocin in a dosage range of 4-400 International Units.

67~~99~~. A method of making a composition comprising combining a 5-HTIA agonist/5-HT_2A antagonist, an oxytocin receptor (OXTR) agonist, and a pharmaceutically acceptable carrier.

68~~100~~. The method of claim 67~~99~~, comprising combining trazodone, oxytocin, and a pharmaceutically acceptable carrier.

69~~101~~. Use of a 5-HT_{2A} antagonist and an oxytocin receptor (OXTR) agonist in the manufacture of a composition for ~~A method of~~ treating a sexual disorder in a subject. ~~comprising administering to the subject a composition according to claim 93~~.

70~~102~~. The use~~method~~ of claim 69~~101~~, wherein the sexual disorder is hypoactive sexual desire disorder (HSDD).

71~~103~~. The use~~method~~ of claim 69~~101~~, wherein the sexual disorder is female orgasm disorder (FOD).

72~~104~~. The use~~method~~ of claim 69~~101~~, wherein the sexual disorder is female sexual arousal disorder (FSAD).

73~~105~~. The use~~method~~ of claim 69~~101~~, wherein the sexual disorder is sexual pain dysfunction.

74~~106~~. The use~~method~~ of claim 69~~101~~, wherein the sexual disorder is male HSDD.

75~~107~~. Use of a 5-HT_{2A} antagonist and an oxytocin receptor (OXTR) agonist in the manufacture of a composition for ~~A method of~~ treating male sexual performance anxiety in a subject. ~~comprising administering to the subject a composition according to claim 93.~~

76~~108~~. Use of a 5-HT_{2A} antagonist and an oxytocin receptor (OXTR) agonist in the manufacture of a composition for ~~A method of~~ treating male orgasmic disorder (MOD). ~~in a subject comprising administering to the subject a composition according to claim 93.~~

77~~109~~. Use of a 5-HT_{2A} antagonist and an oxytocin receptor (OXTR) agonist in the manufacture of a composition for ~~A method of~~ treating a diagnostic and statistical manual of mental disorders (DSM-IV) disorder in a subject ~~comprising administering to the subject a composition according to claim 9~~3.

78~~110~~. Use of a 5-HT_{2A} antagonist and an oxytocin receptor (OXTR) agonist in the manufacture of a composition for ~~A method of~~ treating erectile dysfunction (ED) in a subject ~~comprising administering to the subject a composition according to claim 93~~.

79~~111~~. Use of a 5-HT_{2A} antagonist and an oxytocin receptor (OXTR) agonist in the manufacture of a composition for ~~A method of~~ treating cognitive disorders in a subject ~~comprising administering to the subject a composition according to claim 93~~.

80~~112~~. The use of~~method in~~ claim 79~~111~~, wherein the cognitive disorder is dementia.

81~~113~~. The use of~~method in~~ claim 80~~112~~, wherein the dementia is Alzheimer's disease, frontotemporal lobar degeneration, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, multi-infarct dementia, dementia resulting from infections affecting the central nervous system, dementia resulting from chronic drug use, dementia resulting from hydrocephalus, dementia resulting from brain injury, or dementia resulting from a brain tumor.

82~~114~~. The use of~~method in~~ claim 79~~111~~, wherein the cognitive disorder is cognitive disability.

83~~115~~. The use of ~~method in~~ claim 82~~114~~, wherein the cognition disability is schizophrenia, schizoaffective disorder, bipolar disorder, or major depression.

84~~116~~. The use of~~method in~~ claim 79~~111~~, wherein the cognitive disorder is developmental cognitive impairment.

85~~117~~. The use of~~method in~~ claim 84~~116~~, wherein the developmental cognitive impairment is Autism, Asperger' s syndrome, or pervasive developmental disorder.

86~~118~~. The use of~~method in~~ claim 79~~111~~, wherein the cognitive disorder is mild cognitive decline.

87~~119~~. Use of a 5-HT_{2A} antagonist and an oxytocin receptor (OXTR) agonist in the manufacture of a composition for ~~A method of~~ enhancing cognition in a subject. ~~comprising administering to the subject a composition according to claim 93.~~

88~~120~~. The use of ~~method in~~ claim 87~~119~~, wherein enhancing cognition is improving mental activities such as attention, perception, learning, memory, language, planning, decision-making, organization, conceptualization, reorganization, synthesis of facts, synthesis of data, recall, calculation, spatiotemporal visualization, mental flexibility, creativity, or the ability to accept challenging intellectual or cultural pursuits.

89~~121~~. The use of ~~method of~~ any one of claims 69-88 ~~101, 107, 108, 109, 110, 111, or 119~~ wherein the composition is administered orally.

90~~122~~. _____ The use of ~~method of~~ any one of claims 69-88 ~~101, 107, 108, 109, 110, 111, or 119~~ wherein the composition is administered topically.

91~~123~~. _____ The use of~~method of~~ any one of claims 69-88 ~~101, 107, 108, 109, 110, 111, or 119~~ wherein the subject is diagnosed and being treated for depression.

92~~124~~. _____ The use of~~method of~~ any one of claims 69-88 ~~101, 107, 108, 109, 110, 111, or 119~~ wherein the subject is not undergoing treatment for depression.

93~~125~~. _____ The use of~~method of~~ any one of claims 69-88 ~~101, 107, 108, 109, 110, 111, or 119~~ wherein the subject is concurrently prescribed an additional therapeutic agent.

94~~126~~. _____ The use of ~~method of~~ any one of claims 69-88 ~~101, 107, 108, 109, 110, 111, or 119~~ wherein the subject is concurrently not prescribed an additional therapeutic agent.

95~~127~~. _____ An extended release composition comprising a 5-HT_{2A} antagonist, an oxytocin receptor (OXTR) agonist, and a pharmaceutically acceptable carrier.

96~~128~~. _____ The composition of claim 61~~93~~, wherein the composition is suitable for oral administration.

97~~129~~. _____ The composition of claim 61~~93~~, wherein the composition is suitable for topical administration.

98~~130~~. _____ A kit comprising a composition according to claim 61~~93~~ and a label providing instructions for administration of the composition to a subject for treating or ameliorating a sexual disorder or symptoms thereof in the subject.

99~~131~~. _____ A kit comprising a composition according to claim 61~~93~~ and a label providing instructions for administration of the composition to a subject for treating or ameliorating male sexual performance anxiety or symptoms thereof in the subject.

100~~132~~. A kit comprising a composition according to claim 61~~93~~ and a label providing instructions for administration of the composition to a subject for treating or ameliorating cognitive disorders or symptoms thereof in the subject.

101~~133~~. A kit comprising a composition according to claim 61~~93~~ and a label providing instructions for administration of the composition to a subject for enhancing cognition or symptoms thereof in the subject.

102~~134~~. A single dosage composition comprising a 5-HT_{2A} antagonist, an oxytocin receptor (OXTR) agonist and a pharmaceutically acceptable carrier.

~~135. A method of treating a sexual disorder in a subject comprising administering to the subject a 5-HT_{2A} antagonist and an oxytocin receptor (OXTR) agonist.~~

~~136. A method of treating a diagnostic and statistical manual of mental disorders (DSM-IV-TR) sexual, cognitive, or mood disorder in a subject comprising administering to the subject a 5-HT_{2A} antagonist and an oxytocin receptor (OXTR) agonist.~~

~~137. A method of treating erectile dysfunction (ED) in a subject comprising administering to the subject a 5-HT_{2A} antagonist and an oxytocin receptor (OXTR) agonist.~~

~~138. A method of treating male sexual performance anxiety in a subject comprising administering to the subject a 5-HT_{2A} antagonist and an oxytocin receptor (OXTR) agonist.~~

~~139. A method of treating male orgasmic disorder (MOD) in a subject comprising administering to the subject a 5-HT_{2A} antagonist and an oxytocin receptor (OXTR) agonist.~~

~~140. A method of treating cognitive disorders in a subject comprising administering to the subject a 5-HT_{2A} antagonist and an oxytocin receptor (OXTR) agonist.~~

~~141. A method of enhancing cognition in a subject comprising administering to the subject a 5-HT_{2A} antagonist and an oxytocin receptor (OXTR) agonist.~~

103~~142~~. A method of making a composition comprising combining a 5-HT_{IA} receptor agonist and a pharmaceutically acceptable carrier such that the composition comprises a range of 25-450 mg of a 5-HT_{IA} receptor agonist and an oxytocin receptor (OXTR) agonist.

104~~143~~. A method of making a composition comprising combining a 5-HT_{IA} agonist/5-HT_{2A} antagonist and a pharmaceutically acceptable carrier such that the composition comprises a range of 25-450 mg of a 5-HT_{1A} agonist/5-HT_{2A} antagonist ~~5-HT_{2A} antagonist~~ and an oxytocin receptor (OXTR) agonist.

105~~144~~. A method of making a composition comprising combining an oxytocin receptor (OXTR) agonist and a pharmaceutically acceptable carrier such that the composition comprises a range of 4-400 International Units of an oxytocin receptor (OXTR) agonist and a 5-HT_{2A} antagonist.

106~~145~~. A composition comprising a norepinephrine-dopamine reuptake inhibitor, an oxytocin receptor (OXTR) agonist, and a pharmaceutically acceptable carrier.

107~~146~~. The composition of claim 106~~145~~, comprising bupropion and oxytocin.

108~~147~~. The composition of claim 106~~145~~, comprising bupropion in a dosage range of 200-450 mg.

109~~148~~. The composition of claim 106~~145~~, comprising oxytocin in a dosage range of 4-400 International Units.

110~~149~~. The composition of claim 106~~145~~, comprising bupropion in a dosage range of 200-450 mg and oxytocin in a dosage range of 4-400 International Units.

111~~150~~. A method of making a composition comprising combining a norepinephrine-dopamine reuptake inhibitor, an oxytocin receptor (OXTR) agonist, and a pharmaceutically acceptable carrier.

112~~151~~. The method of claim 111~~150~~, comprising combining bupropion, oxytocin, and a pharmaceutically acceptable carrier.

113~~152~~. Use of a norepinephrine-dopamine reuptake inhibitor and an oxytocin receptor (OXTR) agonist in the manufacture of a composition for ~~A method of~~ treating a sexual disorder in a subject. ~~comprising administering to the subject a composition according to claim 145.~~

114~~153~~. The use ~~method~~ of claim 113~~152~~, wherein the sexual disorder is hypoactive sexual desire disorder (HSDD).

115~~154~~. The use ~~method~~ of claim 113~~152~~, wherein the sexual disorder is female orgasm disorder (FOD).

116~~155~~. The use ~~method~~ of claim 113~~152~~, wherein the sexual disorder is female sexual arousal disorder (FSAD).

117~~156~~. The use~~method~~ of claim 113~~152~~, wherein the sexual disorder is sexual pain dysfunction.

118~~157~~. The use~~method~~ of claim 113~~152~~, wherein the sexual disorder is male HSDD.

119~~158~~. Use of a norepinephrine-dopamine reuptake inhibitor and an oxytocin receptor (OXTR) agonist in the manufacture of a composition for ~~A method of~~ treating male sexual performance anxiety in a subject. ~~comprising administering to the subject a composition according to claim 145.~~

120~~159~~. Use of a norepinephrine-dopamine reuptake inhibitor and an oxytocin receptor (OXTR) agonist in the manufacture of a composition for ~~A method of~~ treating a diagnostic and statistical manual of mental disorders (DSM-IV-TR) disorder in a subject. ~~comprising administering to the subject a composition according to claim 145.~~

121~~160~~. Use of a norepinephrine-dopamine reuptake inhibitor and an oxytocin receptor (OXTR) agonist in the manufacture of a composition for ~~A method of~~ treating erectile dysfunction (ED) in a subject. ~~comprising administering to the subject a composition according to claim 145.~~

122~~161~~. Use of a norepinephrine-dopamine reuptake inhibitor and an oxytocin receptor (OXTR) agonist in the manufacture of a composition for ~~A method of~~ treating male orgasmic disorder (MOD) in a subject. ~~comprising administering to the subject a composition according to claim 145.~~

123~~162~~. Use of a norepinephrine-dopamine reuptake inhibitor and an oxytocin receptor (OXTR) agonist in the manufacture of a composition for ~~A method of~~ treating cognitive disorders in a subject. ~~comprising administering to the subject a composition according to claim 145.~~

124~~163~~. The use of ~~method in~~ claim 123 ~~162~~, wherein the cognitive disorder is dementia.

125~~164~~. The use of ~~method in~~ claim 124~~163~~, wherein the dementia is Alzheimer's disease, frontotemporal lobar degeneration, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, multi-infarct dementia, dementia resulting from infections affecting the central nervous system, dementia resulting from chronic drug use, dementia resulting from hydrocephalus, dementia resulting from brain injury, or dementia resulting from a brain tumor.

126~~165~~. The use of ~~method in~~ claim 123~~162~~, wherein the cognitive disorder is cognitive disability.

127~~166~~. The use of ~~method in~~ claim 126~~165~~, wherein the cognition disability is schizophrenia, schizoaffective disorder, bipolar disorder, or major depression.

128~~167~~. The use of~~method in~~ claim 123~~162~~, wherein the cognitive disorder is developmental cognitive impairment.

129~~168~~. The use of~~method in~~ claim 128~~167~~, wherein the developmental cognitive impairment is Autism, Asperger'~~-~~s syndrome, or pervasive developmental disorder.

130~~169~~. The use of~~method in~~ claim 123~~162~~, wherein the cognitive disorder is mild cognitive decline.

131~~170~~. Use of a norepinephrine-dopamine reuptake inhibitor and an oxytocin receptor (OXTR) agonist in the manufacture of a composition for ~~A method of~~ enhancing cognition in a subject. ~~comprising administering to the subject a composition according to claim 145.~~

132~~171~~. The ~~method~~ use of claim 131~~in claim 170~~, wherein enhancing cognition comprises improving mental activities such as attention, perception, learning, memory, language, planning, decision-making, organization, conceptualization, reorganization, synthesis of

facts, synthesis of data, recall, calculation, spatiotemporal visualization, mental flexibility, creativity, or the ability to accept challenging intellectual or cultural pursuits.

133~~172~~. The use~~method~~ of any one of claims 113-132 ~~152, 158, 159, 160, 161, 162, or 170~~ wherein the composition is administered orally.

134~~173~~. The use~~method~~ of any one of claims 113-132 ~~152, 158, 159, 160, 161, 162, or 170~~ wherein the composition is administered topically.

135~~174~~. The use~~method~~ of any one of claims 113-132~~152, 158, 159, 160, 161, 162, or 170~~ wherein the subject is diagnosed and being treated for depression.

136~~175~~. The use~~method~~ of any one of claims 113-132~~152, 158, 159, 160, 161, 162, or 170~~ wherein the subject is not undergoing treatment for depression.

137~~176~~. The use~~method~~ of any one of claims 113-132~~152, 158, 159, 160, 161, 162, or 170~~ wherein the subject is concurrently prescribed an additional therapeutic agent.

138~~177~~. The use~~method~~ of any one of claims 113-132 ~~152, 158, 159, 160, 161, 162, or 170~~ wherein the subject is concurrently not prescribed an additional therapeutic agent.

139~~178~~. An extended release composition comprising a norepinephrine-dopamine reuptake inhibitor, an oxytocin receptor (OXTR) agonist, and a pharmaceutically acceptable carrier.

140~~179~~. The composition of claim 106~~145~~, wherein the composition is suitable for oral administration.

141~~180~~. The composition of claim 106~~145~~, wherein the composition is suitable for topical administration.

142~~181~~. A kit comprising a composition according to claim 106~~145~~ and a label providing instructions for administration of the composition to a subject for treating or ameliorating a sexual disorder or symptoms thereof in the subject.

143~~182~~. A kit comprising a composition according to claim 106~~145~~ and a label providing instructions for administration of the composition to a subject for treating or ameliorating male sexual performance anxiety or symptoms thereof in the subject.

144~~183~~. A kit comprising a composition according to claim 106~~145~~ and a label providing instructions for administration of the composition to a subject for treating or ameliorating cognitive disorders or symptoms thereof in the subject.

145~~184~~. A kit comprising a composition according to claim 106~~145~~ and a label providing instructions for administration of the composition to a subject for enhancing cognition or symptoms thereof in the subject.

146~~185~~. A single dosage composition comprising a norepinephrine-dopamine reuptake inhibitor, an oxytocin receptor (OXTR) agonist, and a pharmaceutically acceptable carrier.

~~186. A method of treating a sexual disorder in a subject comprising administering to the subject a norepinephrine-dopamine reuptake inhibitor and an oxytocin receptor (OXTR) agonist.~~

~~187. A method of treating a diagnostic and statistical manual of mental disorders (DSM-IV-TR) disorder in a subject comprising administering to the subject a norepinephrine-dopamine reuptake inhibitor and an oxytocin receptor (OXTR) agonist.~~

~~188. A method of treating erectile dysfunction (ED) in a subject comprising administering to the subject a norepinephrine-dopamine reuptake inhibitor and an oxytocin receptor (OXTR) agonist.~~

~~189. A method of treating male sexual performance anxiety in a subject comprising administering to the subject a norepinephrine-dopamine reuptake inhibitor and an oxytocin receptor (OXTR) agonist.~~

~~190. A method of treating male orgasmic disorder (MOD) in a subject comprising administering to the subject a norepinephrine-dopamine reuptake inhibitor and an oxytocin receptor (OXTR) agonist.~~

~~191. A method of treating cognitive disorders in a subject comprising administering to the subject a norepinephrine-dopamine reuptake inhibitor and an oxytocin receptor (OXTR) agonist.~~

~~192. A method of enhancing cognition in a subject comprising administering to the subject a norepinephrine-dopamine reuptake inhibitor and an oxytocin receptor (OXTR) agonist.~~

147~~193~~. A method of making a composition comprising combining a norepinephrine-dopamine reuptake inhibitor and a pharmaceutically acceptable carrier such that the composition comprises a range of 200-450 mg of a norepinephrine-dopamine reuptake inhibitor and an oxytocin receptor (OXTR) agonist.

148~~194~~. A method of making a composition comprising combining an oxytocin receptor (OXTR) agonist and a pharmaceutically acceptable carrier such that the composition comprises a range of 4-400 International Units of an oxytocin receptor (OXTR) agonist and a norepinephrine-dopamine reuptake inhibitor.

~~195. A composition comprising flibanserin and bupropion, and a pharmaceutically acceptable carrier.~~

~~196. The composition of claim 195, comprising bupropion in a dosage range of 1-450 mg~~

~~197. The composition of claim 195, comprising flibanserin in a dosage range of 25-450 mg.~~

~~198. The composition of claim 195, comprising flibanserin in a dosage range of 25-450 mg and bupropion in a dosage range of 1-450 mg.~~

149~~199~~. A method of making a composition comprising combining flibanserin, bupropion, and a pharmaceutically acceptable carrier.

150. Use of flibanserin and bupropion in the manufacture of a composition for the treatment of a male sexual disorder in a subject.

151~~200~~. The use of claim 150, wherein the male sexual disorder is ~~A method of treating~~ male HSDD. ~~in a subject comprising administering to the subject a composition according to claim 195.~~

152~~201~~. The use of claim 150, wherein the male sexual disorder is~~A method of treating~~ male sexual performance anxiety. ~~in a subject comprising administering to the subject a composition according to claim 195.~~

153~~202~~. The use of claim 150, wherein the male sexual disorder is ~~A method of treating~~ male orgasmic disorder (MOD). ~~in a subject comprising administering to the subject a composition according to claim 195.~~

154~~203~~. The use of claim 150, wherein the male sexual disorder is ~~A method of treating~~ erectile dysfunction (ED). ~~in a subject comprising administering to the subject a composition according to claim 195.~~

155~~204~~. The use~~method~~ of any one of claims 150-154 ~~200, 201, 202, or 203~~ wherein the composition is administered orally.

156~~205~~. The use~~method~~ of any one of claims 150-154 ~~200, 201, 202, or 203~~ wherein the composition is administered topically.

157~~206~~. The use~~method~~ of any one of claims 150-154~~200, 201, 202, or 203~~ wherein the subject is diagnosed and being treated for depression.

158~~207~~. The use~~method~~ of any one of claims 150-154~~200, 201, 202, or 203~~ wherein the subject is not undergoing treatment for depression.

159~~208~~. The use~~method~~ of any one of claims 150-154~~200, 201, 202, or 203~~ wherein the subject is concurrently prescribed an additional therapeutic agent.

160~~209~~. The use~~method~~ of any one of claims 150-154~~200, 201, 202, or 203~~ wherein the subject is concurrently not prescribed an additional therapeutic agent.

~~210. An extended release composition comprising flibanserin, bupropion, and a pharmaceutically acceptable carrier.~~

~~211. The composition of claim 195, wherein the composition is suitable for oral administration.~~

~~212. The composition of claim 195, wherein the composition is suitable for topical administration.~~

161~~213~~. A kit comprising a composition comprising flibanserin and bupropion, and a pharmaceutically acceptable carrier, ~~according to claim 195~~ and a label providing instructions for administration of the composition to a subject for treating or ameliorating male HSDD or symptoms thereof in the subject.

162~~214~~. A kit comprising a composition comprising flibanserin and bupropion, and a pharmaceutically acceptable carrier, ~~according to claim 195~~ and a label providing instructions for administration of the composition to a subject for treating or ameliorating male sexual performance anxiety or symptoms thereof in the subject.

163~~215~~. A kit comprising a composition comprising flibanserin and bupropion, and a pharmaceutically acceptable carrier, ~~according to claim 195~~ and a label providing instructions for administration of the composition to a subject for treating or ameliorating erectile dysfunction (ED) or symptoms thereof in the subject.

164. The use of any one of claims 150-160, or the kit of any one of claims 161-163, wherein the composition comprises bupropion in a dosage range of 1-450 mg.

165. The use of any one of claims 150-160, or the kit of any one of claims 161-163, wherein the composition comprises flibanserin in a dosage range of 25-450 mg.

166. The use of any one of claims 150-160, or the kit of any one of claims 161-163, wherein the composition comprises flibanserin in a dosage range of 25-450 mg and bupropion in a dosage range of 1-450 mg.

~~216. A single dosage composition comprising flibanserin, bupropion, and a pharmaceutically acceptable carrier.~~

~~217. A method of treating male HSDD in a subject comprising administering to the subject flibanserin and bupropion.~~

~~218. A method of treating erectile dysfunction (ED) in a subject comprising administering to the subject flibanserin and bupropion.~~

~~219. A method of treating male sexual performance anxiety in a subject comprising administering to the subject flibanserin and bupropion.~~

~~220. A method of treating male orgasmic disorder (MOD) in a subject comprising administering to the subject flibanserin and bupropion.~~

~~221. A method of making a composition comprising combining flibanserin, bupropion, and a pharmaceutically acceptable carrier such that the composition comprises a range of 25-450 mg flibanserin and bupropion.~~

~~222. A method of making a composition comprising combining flibanserin, bupropion, and a pharmaceutically acceptable carrier such that the composition comprises a range of 1-450 mg of bupropion and flibanserin.~~